And there was a twitter supposedly quoting Sandy Walsh, the FDA spokesperson, as saying there were, in fact, no labeling issues. Oddly, the PR from Watson, Amphastar's marketing partner, only claims approval for the largest doses, which would only be a small fraction of the market. I suspect that is a misstatement of reality, though.
So now the only big question on this front is whether or not MNTA claims infringement, and what the odds are of success. In the immediate time frame, success would be measured in getting a temporary injunction.
I increased my position 1/3 today in the low 13s, FWIW.
Cheer, Tuck |
